Clinical trials: Anxiety, Generalized
Generalized Anxiety Disorder
CES for the Treatment of GAD in Young Adults
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
- Trial name
- NCT06124014
- Testing
- At-Home Stimulation
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Electromedical Products International, Inc.
Anxiety, Anxiety Disorders
Generalized Anxiety Disorder Adjunct Study
This study is being carried out to see if extended release quetiapine fumarate (Seroquel®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) / serotonin-norepinephrine reuptake inhibitor (SNRI) therapy is…
- Conditions
- Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
- Trial name
- NCT00534599
- Testing
- quetiapine fumarate XR
- Where
- 53 sites in United States
- Volunteers
- 409 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Fibromyalgia
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is…
- Conditions
- Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder
- Trial name
- NCT00071708
- Testing
- Duloxetine Hydrochloride
- Where
- 13 sites in Australia
- Sponsor
- Eli Lilly and Company
General Anxiety Disorder
Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the…
- Trial name
- NCT07477990
- Testing
- App AURORA (Digital Therapy) + conventional treatment, Pharmacological conventional treatment
- Where
- Mexico
- Volunteers
- 162 people
- Sponsor
- Psicofarma, S.A. De C.V.
Generalized Anxiety Disorder
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with…
- Trial name
- NCT00800280
- Testing
- PD 0332334, cimetidine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Anxiety Neuroses, Anxiety States, Neurotic
A Study in Pediatric Participants With Generalized Anxiety Disorder
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
- Conditions
- Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
- Trial name
- NCT01226511
- Testing
- Duloxetine
- Where
- 24 sites in United States, Mexico and 1 more
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Anxiety, Generalized Anxiety Disorder
Brain Stimulation & Generalized Anxiety Study
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
- Conditions
- Anxiety, Generalized Anxiety Disorder, Generalized Anxiety
- Trial name
- NCT04751864
- Testing
- Cranial Electrotherapy Stimulator (CES) Device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Generalized Anxiety Disorder
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental…
- Trial name
- NCT06701903
- Testing
- ITI-1284 10 mg, ITI-1284 20 mg
- Where
- 51 sites in United States, Bulgaria and 3 more
- Volunteers
- 570 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bi-Polar Disorder, Autism Spectrum Disorder (ASD)
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
- Conditions
- Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder
- Trial name
- NCT07329673
- Testing
- Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Qbtech AB
ADHD, Depression Disorders
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled…
- Conditions
- ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized
- Trial name
- Rx Meds Gaize (NCT07389473)
- Testing
- Prescription Psychotropic Medications
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gaize
Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard…
- Trial name
- NCT07620340
- Testing
- AI-Digital CBT, Cognitive Behavioural Therapy
- Volunteers
- 400 people
- Sponsor
- PsyScale
Generalized Anxiety Disorder
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
- Trial name
- NCT00616655
- Testing
- eszopiclone
- Where
- 57 sites in United States
- Volunteers
- 456 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anxiety Generalized
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects…
- Trial name
- NCT05407064
- Testing
- MM120
- Where
- 22 sites in United States
- Volunteers
- 198 people
- Sponsor
- Definium Therapeutics US, Inc.
Generalized Anxiety Disorder
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
- Trial name
- NCT06741228
- Testing
- DT120
- Where
- 34 sites in United States
- Volunteers
- 214 people
- Sponsor
- Definium Therapeutics US, Inc.
Anxiety Disorder Generalized
A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo- and active-controlled study to assess the efficacy and safety of CD-008-0045 in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT04598867
- Testing
- CD-008-0045, Afobazol
- Volunteers
- 200 people
- Sponsor
- ChemRar Research and Development Institute, LLC
Obsessive Compulsive Disorder (OCD), Bipolar Disorders
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
- Conditions
- Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
- Trial name
- NCT06823024
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Psyrin Inc.
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Generalized Anxiety Disorder
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
- Trial name
- NCT06809595
- Testing
- DT120
- Where
- 36 sites in United States, Czechia and 4 more
- Volunteers
- 245 people
- Sponsor
- Definium Therapeutics US, Inc.
Anxiety Disorders
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder
- Trial name
- NCT00374166
- Testing
- SSR149415, Paroxetine
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
- Trial name
- NCT00595231
- Testing
- SYN111
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Biotie Therapies Inc.